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Abstract: Background and Aim: Adverse effects are common in children treated with antiepileptic
medications and may affect parental beliefs about treatment. The aim of the study was to investigate
the relationship between adverse effects and parental beliefs about antiepileptic drugs used for the
treatment of their children. Methods: The study was performed at the University Children’s Hospital,
Belgrade, Serbia from 2013–2015. Parents of children treated with valproic acid, carbamazepine or
lamotrigine, were eligible. They were asked to fill in the Beliefs about Medications Questionnaire
(BMQ) and The Liverpool Adverse Events Profile (LAEP). Results: Parents of 127 children (average
age 9.88 ± 4.16 years) of whom 111 had epilepsy (67 generalized, 44 focal) and 16 with febrile
seizures participated in the study. Nervousness and/or agitation, weight gain, restlessness, headache,
difficulty in concentrating, feeling of aggression and upset stomach were most frequent adverse
effects, reported in 37% of the population. BMQ-specific necessity scores significantly correlated
with parental education; parents with elementary school showed lower scores than those with
higher education. The presence of difficulty in concentrating of their child was associated with
higher BMQ concern scores (20.73 ± 4.25 vs. 18.99 ± 3.60, p = 0.043) as well as necessity scores
(18.42 ± 3.31 vs. 16.40 ± 2.73, p = 0.017). Higher scores of BMQ-general overuse were reported in the
presence of a headache (8.79 ± 2.81 vs. 7.64 ± 2.72, p = 0.027). Conclusions: The main finding of our
study is that parental beliefs about antiepileptic drugs were associated with the presence of adverse
effects. Understanding this relationship could allow physicians and pharmacists to structure better
educational programs for parents of children treated with antiepileptic drugs. Education should
be more focused towards understanding the adverse effects of antiepileptics which could alleviate
parental concerns and strengthen their beliefs about the necessity of medication use in their children.
Keywords: antiepileptic drugs; children; parents; beliefs about medications; adverse events
1. Introduction
Antiepileptic drugs are commonly prescribed to control epileptic seizures. They are associated
with adverse effects in approximately 50% of paediatric patients on monotherapy [1,2]. The most
commonly used antiepileptic drugs such as valproic acid, carbamazepine and lamotrigine have been
associated with gastrointestinal disturbances, loss of appetite and nausea, weight gain, tremor, rash and
fatigue/tiredness [3]. However, the reports of adverse effect prevalence of antiepileptic drugs are
inconsistent, probably due to the different methodology used for assessing adverse effects such as
spontaneous reporting or specially designed questionnaires for side effects [4]. Whereas some adverse
effects of antiepileptics are readily assessed (weight gain/loss, rash), others are difficult to observe
and rely on subjective patient reporting [5]. The Liverpool Adverse Events Profile (LAEP) has been
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developed with the aim to quantify patients’ perceptions of adverse effects of antiepileptic drugs [6–9].
LAEP is a validated 19-item questionnaire commonly used for quantification of adverse effects of most
frequently used antiepileptic drugs [5,10–14].
Medications used in treatment of epilepsy have been related to nonadherence and reduced quality
of life, particularly cognitive and neurological impairment [15,16]. Nonadherence has been associated
with perceptual barriers such as concerns about adverse effects, doubts about the need for medicines
or gaps in knowledge [17,18]. Horne et al. postulated that adherence to treatments is the result of
the interplay between patients’ beliefs about the necessity of therapy and their concerns about the
potential adverse consequences of treatment [19].
The adherence of young children to medications depends on their parents’ or caregivers’ decisions
to administer medicines appropriately. Various barriers to medication adherence for children and their
parents have been reported. Parental lack of understanding the disease, worries about the effectiveness
and side effects of medications, polypharmacy, the length of treatment duration is some of the reasons
for nonadherence [20,21]. Moreover, adverse effects of antiepileptic drugs may be a reason for a parent
to discontinue treatment, at least for some time, if the child has well-controlled seizure disorders [16].
The aim of this study was to investigate how the presence of adverse effects of antiepileptic drugs
influences parental beliefs about medications.
2. Methods
2.1. Patient’s Characteristics
The study was performed at the University Children’s Hospital in Belgrade, Serbia during the
period 2013–2015. The study was approved by the Ethics Committee of the University Children’s
Hospital (Nr 017/6, 26/56 Date 18 March 2013). The research was performed according to the Code
of Ethics (Declaration of Helsinki). All participants gave their informed consent before they were
included in the study.
Parents of children, aged 0–18 years diagnosed with epilepsy or febrile seizures, who were
treated with valproic acid, lamotrigine or carbamazepine for at least six months, were included
in the study after signing the informed consent. These drugs were selected since they were most
frequently used, as monotherapy, in patients with seizures in our hospital. The main inclusion
criteria were: good seizure control of the child with monotherapy, healthy neurological and cognitive
development, normal school function (if applicable), normal magnetic resonance imaging scan,
normal computed tomography and no other severe co-morbidities (endocrinopathies, liver or kidney
diseases, systemic disorders). All patients who fulfilled the inclusion criteria were eligible for the study.
The following data were obtained from the patients: gender, age, seizure type, duration of therapy,
drug dose and serum concentration level of the drug measured on the day that the parent completed
the questionnaire. Parents were asked about their age, gender and educational attainment.
All participants were parents of ambulatory patients and they had been invited to complete the
LAEP and Beliefs about Medicines Questionnaire (BMQ) during a control visit at the hospital.
2.2. LAEP
The LAEP is a self-report questionnaire developed to assess the frequency of side effects of
antiepileptic drugs. It includes 19 items presented as a checklist of symptoms that may have occurred
in the last four weeks. The frequency of side effects is rated on a 4-point Likert scale with 1- never a
problem; 2- rarely a problem; 3- sometimes a problem; and 4- always a problem [6,8]. Results can be
individually assessed or added up to total scores which range from 19–76 [5,22]. High scores indicate
more frequent symptom reporting. The LAEP was translated into the Serbian language. Translations
were then evaluated by a group of six native speakers to ensure that the resulting translations are
correct, clear and understandable. Back-translation into English was performed by two independent
translators native in the target language.
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2.3. BMQ
In order to examine parental views about their child’s treatment, we used the validated
BMQ [19,23]. The BMQ is an 18-item questionnaire, divided into two sections BMQ-Specific
and BMQ-General.
The BMQ-Specific was used to measure parental beliefs about the necessity for treatment with
antiepileptic drugs as well as concerns or worries associated with their use. Parents were instructed
to answer questions about their child’s treatment. The two subscales of BMQ-Specific questionnaire,
necessity of medication use and concerns are each assessed by five questions. Necessity is assessed
through questions such as “My child’s health at present depends on these medications” and an example
of concerns questions is “I sometimes worry about the long-term effects of these medicines on my
child.”
The BMQ-General was used to assess more general beliefs about medications [19].
The BMQ-General is divided into General Harm associated with medicines use (five questions, that is,
“Medicines do more harm than good”) and General Overuse (three questions, that is, “Doctors place
too much trust in medicines”).
All items were scored on a 5-point Likert scale, ranging from strongly disagree (1 point) to strongly
agree (5 points). Each BMQ subscale was summed and the higher scores represented stronger beliefs
in every subscale. The subscales were also transformed into dichotomous variables where the summed
score is split at the midpoint [19]. Scores above the midpoint indicated stronger beliefs in each subscale.
A Necessity-Concerns Differential was calculated as a difference between BMQ-Necessity and
BMQ-Concerns scores. This differential can be thought of as an individual cost-benefit analysis where
costs are represented by concerns and weighed against benefit (perceived as necessity beliefs) [19].
The BMQ scales were originally developed for adults. However, they have been used to
measure parental views about needs and concerns related to their child’s medications [16,24–26].
Internal consistency was tested in our sample and Cronbach’s alpha was between 0.65–0.81 in all
subscales. In order to assess internal reliability of the BMQ questionnaire we conducted confirmatory
Factor analysis through Principal Component Analysis. The Kaiser-Meyer-Olkin Measure of Sampling
Adequacy is a statistic that indicates the proportion of variance in variables that might be caused
by underlying factors. Since we obtained a high statistic value of 0.753 we are confident that Factor
analysis is suitable for analysis. Using Varimax rotation on extracted factors, we obtained factors that
fit well with the original model (0.62–0.81) and therefore we continued our analysis in line with the
proposed sub-scales (BMQ necessity, BMQ concerns, BMQ overuse, BMQ harm).
2.4. Data Management and Statistical Analysis
Statistical analysis was performed using PASW 18 (SPSS Inc., Chicago, IL, USA). Descriptive
statistics were carried out to characterize the frequency of the variables. Data were expressed as
mean± standard deviation (SD) values or median and interquartile range (IQR). Mann-Whitney U-test
was used to compare BMQ scores. Bivariate Pearson’s correlation was used to assess correlations
between BMQ and LAEP scores. Linear regression was used to explore the impact of age (0–18 years),
gender, seizure type, medication, duration of treatment and parental gender and education level on
LAEP and BMQ scores. The coefficient of determination (R2), the regression coefficient (B), its 95%
confidence interval (CI) and standard error (SE) were used to describe the linear regression model.
Statistical significance was set at p < 0.05.
3. Results
3.1. General Characteristics
In total, parents of 132 children were eligible for the study. Written consent was obtained
from 127 (96.1%) parents and they were included in the study. Out of the 127 parents who filled
in the questionnaires 106 (83.5%) were mothers and the average age of parents was 36 ± 12 years.
Medicina 2018, 54, 60 4 of 10
The majority of children (111, 87.4%) were diagnosed with epilepsy and 16 (12.6%) had febrile seizures.
Sixty-seven patients were diagnosed with generalized onset seizures, (of whom 52 had tonic-clonic
seizures, whereas 15 had absence seizures) and 44 patients were diagnosed with focal onset seizures
(15 had focal aware seizures, 29 developed focal to bilateral tonic-clonic seizures). The mean daily
dose was 589 ± 194 mg of valproic acid, 576 ± 215 mg of carbamazepine and 100 (75–125) mg of
lamotrigine. Serum concentration levels of the drugs were in the reference range for 110 patients
(86.6%). Three patients on valproic acid had elevated concentrations and 14 patients had levels that
were below the reference range (11 on valproic acid, one on carbamazepine and two on lamotrigine).
All concentrations out of range were within 20% deviation of the reference range. Patient characteristics
and parental educational attainment are presented in Table 1.
Table 1. Patient characteristics and parental education level.
Patient Characteristics Total (N = 127)
Age, mean ± SD, years 9.88 ± 4.16
Gender, male n (%) 64 (50.4)
Treatment n (%)
Valproic acid 102 (80.3)
Carbamazepine 13 (10.2)
Lamotrigine 12 (9.5)
Dose n (%)
Valproic acid
20 mg/kg 52 (51.0)
25 mg/kg 11 (10.8)
30 mg/kg 3 (2.9)
≥45 kg 36 (35.3)
Carbamazepine
10 mg/kg 3 (23.1)
20 mg/kg 2 (15.4)
≥45 kg 8 (61.5)
Lamotrigine
3 mg/kg 9 (75.0)
4 mg/kg 1 (8.3)
≥45 kg 2 (16.7)
Treatment duration, median (IQR), years 3 (2-5)
Parental age, mean ± SD, years 36 ± 12
Gender, female n (%) 106 (83.5)
Parental education level n (%)
Primary school 28 (22.0)
Secondary school 83 (65.4)
University 16 (12.6)
3.2. Adverse Effects
The mean LAEP score was 23.36 ± 4.53. The most frequent LAEP-defined specific adverse
effects were nervousness and/or agitation (22.9%), weight gain (18.1%), restlessness (17.3%), headache
(16.5%), difficulty in concentrating (11.8%), feeling of aggression (11.0%) and upset stomach (10.2%).
The mean scores of adverse effects are presented in the Figure 1. There were no statistically significant
differences in the overall LAEP score or in specific adverse effects among patients on valproic acid,
carbamazepine and lamotrigine. Age, gender, duration of treatment and parental education level and
gender had no impact on the LAEP score.
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Figure 1. The mean scores of adverse effects as defined by the Liverpool Adverse Event profile (LAEP)
with antiepileptic drugs.
3.3. Parental Beliefs about Medications
The mean necessity score in our population was 19.17 ± 3.76. Most parents (91%) had strong
beliefs about the need for treatment (BMQ necessity score ≥ 16). The majority of parents (61.4%)
also reported strong concerns about their child’s medication and the mean BMQ concerns score
was 16.70 ± 2.92. Parents had concerns about potential long-term adverse effects of medication use
(65.3% had scores greater than the scale midpoint) and their children becoming dependent upon the
medication (53.5%). BMQ concerns score was weakly but significantly correlated with the LAEP score
(rp = 0.220; p = 0.013).
The mean necessity score was significantly greater than the mean concerns score p < 0.001.
A mean necessity-concerns differential was 2.47± 3.41. The negative necessity-concern differential was
reported by 17.3% of parents and same necessity and concerns score was seen in 9.4% of respondents.
The BMQ harm score was 12.95 ± 3.33 and the BMQ overuse score was 8 [6–10].
3.4. Predictors for BMQ Scores
Parental beliefs about the necessity of their children’s medications were influenced by their
education level and the observed difficulty in concentrating of their child. Parents with elementary
education had lower BMQ necessity scores compared to parents with university education
(18.29± 3.37 vs. 20.61± 3.20, p = 0.04). The presence of difficulty in concentrating increased the necessity
scores in comparison to the absence of the adverse effects (20.73 ± 4.25 vs. 18.99 ± 3.60 respectively,
p = 0.043).
Difficulty in concentrating was also associated with higher concerns score (18.42 ± 3.31 parents
who reported difficulty in concentrating versus 16.40 ± 2.73 parents who did not report the adverse
effect, p = 0.017). Higher scores of medication overuse were reported in the presence of a headache
(8.79 ± 2.81 presence of a headache vs. 7.64 ± 2.72 absence of headache, p = 0.027). Predictors for BMQ
subscale scores are presented in Table 2.
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Table 2. Predictors for Beliefs about Medications Questionnaire (BMQ) subscale scores.
Dependent Value Predictor R2 B (95% CI) SE p-Value
BMQ necessity Parental education level 0.273 1.13 (0.03–2.24) 0.56 0.045
Difficulty in concentrating 0.273 1.08 (0.21–1.96) 0.44 0.016
BMQ concerns Difficulty in concentrating 0.262 1.04 (0.36–1.72) 0.34 0.003
BMQ overuse Headache 0.193 0.70 (0.07–1.32) 0.32 0.029
BMQ-harm not identified
The coefficient of determination (R2), the regression coefficient (B), standard error (SE).
The influence of parental gender on BMQ subscale results was analysed and no statistically
significant differences were observed. Nevertheless, linear regression models were performed for
fathers and mothers separately. Predictive factors associated with the BMQ subscale results for fathers
were not identified. In contrast, the scores of mothers’ BMQ subscales (see Table 3) reflected the overall
results presented in Table 2.
Table 3. Predictors for BMQ subscale results when mothers answered the questionnaire.
Dependent Value Predictor R2 B (95% CI) SE p-Value
BMQ necessity Parental education level 0.300 1.41 (0.20–2.63) 0.61 0.023
Difficulty in concentrating 0.300 1.03 (0.07–1.99) 0.49 0.036
BMQ concerns Difficulty in concentrating 0.231 0.86 (0.16–1.56) 0.35 0.017
BMQ overuse Headache 0.219 0.80 (0.11–1.51) 0.35 0.024
BMQ- harm not identified
4. Discussion
The main finding of our study is that parental beliefs about antiepileptic drugs were associated
with the presence of adverse effects.
The burden of adverse effects in our cohort was low since the LAEP score did not reach the value
of 45 in any patient [22]. Compared to other studies which used the same methodology, we found lower
median LAEP scores (22 vs. 30–45 respectively) [5,10,13,14,27,28]. The reason for this discrepancy
is probably the fact that in all the aforementioned studies, the participants were adult patients with
epilepsy who reported the symptoms themselves. In our study parents were asked to fill in the LAEP
questionnaire without previous preparation for the task. Therefore, their responses were based on
spontaneous observations and it is possible that they overlooked some symptoms which may have
been detected by the patient or a clinician. Moreover, it is possible that the children were not able to
recognize or communicate the adverse effects to the parents. However, Harbord reported the presence
of significant side effects such as aggression, irritability, hyperactivity, rash, headache, gastrointestinal
disturbances and drowsiness in 26% of children with epilepsy [1]. Our results are more consistent
with this study since similar adverse effects were reported in 37% of our population. Other factors
may have contributed to the lower adverse effect burden such as, our cohort was on monotherapy,
they responded to treatment and their serum drug concentration levels were mainly in the reference
range. In contrast, studies have shown that lack of 12-month terminal seizure remission, drug resistance
and polytherapy contribute to a higher burden of adverse effects [10,27,28]. Most common reported
side effects of antiepileptic drugs in the literature were tiredness, memory problems, sleepiness
and difficulty in concentrating [5,14,27]. Nervousness and/or agitation, weight gain, restlessness,
headache, difficulty in concentrating, feeling of aggression and upset stomach were the most frequent
adverse effects observed in our study. A possible reason for the discrepancy of the results may
be that tiredness, memory problems and sleepiness may be subjective symptoms that parents may
overlook or underestimate, whereas nervousness, agitation, weight gain, may be more easily observed.
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Kowski et al. associated the use of lamotrigine with difficulties in concentrating, and although a small
group of patients in our study was on this medication, our results are in accordance because this was
the most common adverse effect reported in this cluster [10].
Most of the parents reported positive beliefs about the necessity of their children’s medication.
The necessity score was somewhat higher compared to another study which involved caregivers of
children treated with antiepileptic drugs (19.17 ± 3.76 vs. 17.97 ± 4.11, respectively) [16]. BMQ has
been used to assess beliefs about medications in parents of asthmatic children and similar results to
ours were reported (18.2 ± 3.5) [25]. The mean concern score was also higher compared to the other
two studies but the necessity-concerns differential score was similar to the study of asthmatic children,
revealing that 25–30% of parents have negative beliefs about their children’s treatment [16,24,25]. This is
an important finding because parental concerns about their children’s treatment have been associated
with lower levels of adherence [24,29,30]. BMQ harm and overuse score were lower compared to the
necessity and concern scores but this was expected since patients were on monotherapy.
Age and gender of the child, duration of treatment, seizure type and medication were not
associated with BMQ subscale scores. Since we found no other study that associates adverse effects of
antiepileptic drugs with parental beliefs about medicines a direct comparison is not possible. Moreover,
we also found no other studies addressing parental beliefs about medicines in which the influence of
the investigated parameters was reported. However, we cannot exclude the possibility that the number
of patients in our study was not sufficient to detect the influence of the investigated parameters.
In contrast, a lower level of parental education was associated with a stronger doubt of the
necessity of their children taking medications to treat seizures. Such results are in accordance with
previous studies which have demonstrated a similar impact of education level on beliefs about the
necessity of medicines use scores [31]. Moreover, parental higher education level was reported to be an
independent predictor of higher epilepsy knowledge [32]. Also, inadequate health literacy of parents
was associated with lower level of adherence in epilepsy patients [30,33].
Difficulty in concentrating was predictive of higher necessity as well as higher concerns scores.
Higher parental BMQ necessity or concerns scores have been associated with asthma symptoms
severity in their children [25,26]. However, the unusual finding in our study was that parents seemed to
identify difficulty in concentrating as an adverse effect of their child’s medication but this strengthened
their belief about the necessity of treatment. A possible explanation could be that parents may have
perceived difficulty in concentrating not only as a possible adverse effect but also as a symptom of
illness. Having doubts about the nature of the symptom could have strengthened parent’s beliefs about
the necessity of treatment concomitantly increasing their concerns. This may be corroborated by the
fact that a headache, a common adverse effect of many medications, was associated with beliefs about
medication overuse. It may be possible that parents were not concerned about headaches because they
recognized them as usual medication side effects and did not perceive them as serious. In contrast,
difficulty in concentrating could have raised concerns about their child’s cognitive development
which could have further affected their beliefs about the necessity of treatment as well as concerns.
Further investigation is needed to elucidate this association.
Although parental gender was not associated with differences in the LAEP score or BMQ subscale
results, we analysed mothers’ and fathers’ answers separately. We did not identify predictive factors
for fathers’ answers but, female parents’ results were in accordance with the overall model. Our results
are in contrast with a study in which male parents expressed more negative beliefs, more abuse beliefs
and more beliefs about damage of the medicines to their children than mothers [34]. However, in our
study fathers constituted a small portion of the population (16.5%) and we can assume that the number
of male parents was insufficient to capture the difference.
There are potential limitations to this study. First, it was a cross-sectional study implying that no
conclusions could be drawn with regard to a causal relationship between adverse effects of antiepileptic
drugs and parental beliefs and concerns about their child’s medication. Second, only patients on
monotherapy with controlled seizures were included in the study which limits generalizability to the
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population of paediatric patients with seizures. Third, parents were not introduced to the content of
LAEP in advance, which could have influenced negatively the number of adverse effects reported in
this study. Fourth, we did not investigate the potential impact of parental socioeconomic status on
BMQ scores.
5. Conclusions
Despite its limitations, this study was the first to quantify adverse effects of antiepileptic drugs
linked to parental perceptions about their child’s treatment. The findings indicate that parents observed
nervousness and/or agitation, weight gain, restlessness, headache, difficulty in concentrating, feeling of
aggression and upset stomach as most frequent adverse effects following monotherapy with valproic
acid, lamotrigine and carbamazepine. Parents perceived their child’s medication as necessary but also
revealed a high concern score associated with the medication use. Moreover, the presence of difficulty
in concentrating raised concerns and strengthened parental beliefs about the necessity of medication
use. In contrast, the presence of headaches was associated with parental beliefs about medication
overuse. Higher education level of parents affected the beliefs about the necessity of medication
use positively.
Further investigation of the relationship between parental beliefs and concerns about medications
and the presence of side effects in a randomised controlled trial is necessary. Understanding this
relationship could allow physicians and pharmacists to structure better educational programs for
parents of children on antiepileptic drugs. Education should be more focused towards understanding
the adverse effects of antiepileptic medications which could alleviate parental concerns and strengthen
their beliefs about the necessity of medication use in their children.
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